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Introduction
Toxicology was once the science of poisons and intoxica-
tion. The scope of topics it covers has broadened and devel-
oped with time, however, so that the present-day field of 
toxicology should be regarded as the ‘science of safety’ 
(Collins et al. 2008). It is anticipated that the role of toxi-
cology will grow in the future, with contributions to safety 
assessments of global importance, such as global planning 
for earth resources, anthropogenic changes in the atmos-
phere, and modern techniques for food production (Manci-
occo et al. 2014; Paterson and Lima 2010; UN 2015). For 
sustainable products, safety assessments must be integrated 
into product development and the application of new tech-
nologies and toxicological evaluations form a key part of 
this safety evaluation (Sianipar et al. 2013). In summary, 
toxicology is a translational science, transferring knowl-
edge from basic science into practical applications to safe-
guard human health and the environment.
The demands on toxicologists are high: along with excel-
lence in their field of basic science—be it biology, chemistry 
or medicine—they must be capable of providing an integrated 
view. Translational approaches require a network system 
in which different specialists work together with a common 
understanding of the problems and how to solve them.
Today, the pharmaceutical and chemical industries need 
universities, first, to train toxicologists, and second, to per-
form research in co-operation with scientists from industry 
to promote the future development of safety science. New 
approaches for safety assessments are required, in particular 
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those aiming to reduce animal experiments, with the ultimate 
vision of developing methods that allow safety assessments 
without animal testing (Adler et al. 2011; Jennings et al. 
2014; Knudsen et al. 2015). Here, academia has to take the 
scientific lead by building up research networks with industry 
that should also include scientists from regulatory institutions.
When assessing risks, toxicologists have to critically 
evaluate findings, drawing on their detailed knowledge of 
a wide range of methods, experimental skills, and subjects 
taught at universities. Hence, universities and postgraduate 
teaching institutions need qualified academic personnel and 
appropriate laboratory facilities for training and research.
Academia-based research is clearly needed to resolve 
open questions of great importance. An example is the 
controversy over the dose–response relationships for 
endocrine-active substances and the underlying molecu-
lar mechanisms. Some scientists believe that the use of 
all endocrine-active substances should be subject to regu-
latory control as they claim they have no dose level with-
out an effect. Others, however, feel that endocrine-active 
substances are also subject to thresholded mechanisms 
(Testai et al. 2013; Zoeller et al. 2014; Autrup et al. 2015). 
This issue will remain controversial in the absence of 
new insights into molecular mechanisms thanks to basic 
research and how these ‘translate’ into apical endpoints 
and adverse effects. This is therefore a question of public 
concern, and research should be performed in independent 
institutions supported by public money. This example once 
again highlights the translational nature of toxicology.
Below we describe the different areas in which applied 
toxicology is in demand. We discuss current scientific ques-
tions of relevance that require innovative answers. We also 
address current topics and challenges in risk assessment 
and how to handle them. Altogether this should illustrate 
the overarching nature of toxicology and its role in safe 
guarding human health and an intact environment.
Toxicology as an applied science
Toxicology enables the assessment of risks originating 
from the exposure of humans, animals and the environment 
to industrial chemicals, plant protection products, biocides, 
medical drugs and devices, and consumer goods, including 
food and cosmetics. Recommendations for the protection 
of workers, consumers, and the environment are derived 
from scientific investigations and assessments of the toxic 
properties of these substances.
Occupational health and safety
Workers must be protected against adverse health effects 
from hazardous substances at the workplace (Jansen 2003; 
Kang 2015; Kogi 2015). Toxicologists assess the health haz-
ards of substances at work and combine this with exposure 
assessments to characterize the risk of adverse health effects. 
They propose occupational exposure limits to reduce risks 
to acceptable levels (Ziegler-Skylakakis 2003). Such hazard 
and risk assessments have to be continuously adapted to new 
toxicological findings; conventionally, these are observed 
toxic effects which are progressively supplemented with tox-
icokinetic and mechanistic data to allow for a more precise 
assessment of the extent and relevance of toxic effects on 
humans. Estimates of the recent and future burden of occu-
pational diseases indicate that occupational cancer is still a 
major problem and will remain so in the future as a result 
of exposure of workers to carcinogens (European Agency for 
Safety and Health at Work 2014). Authoritative occupational 
exposure limits are derived from comprehensive assessments 
of toxicodynamics, toxicokinetics, mechanistic data, and 
the evaluation of the underlying experimental data (MAK 
2015). At the same time, new experimental investigations are 
required to complement the toxicological data, incorporating 
progress made in the toxicological and life sciences (Iavicoli 
and Boccuni 2010). Toxicologists highly trained in both, the 
scientific basis and the toxicological methodology, are indis-
pensable for executing these tasks.
Consumer protection
Consumers are exposed to xenobiotic substances via food, 
cosmetics and other consumer products such as textiles 
and toys. Hazardous substances may be present in food as 
natural constituents or contaminants—of microbial origin 
or from the environment or food packaging (Wölfle and 
Pfaff 2010)—residues of pesticides and veterinary drugs, or 
additives (EFSA 2015a, b; Heberer et al. 2007). The toxico-
logical assessment of xenobiotic substances in food some-
times gains a high level of public interest and presents new 
scientific challenges, as exemplified by a decade of discus-
sion on bisphenol A (Hengstler et al. 2011; EFSA 2015a, 
b). Likewise, substances migrating from textiles and toys 
raise public awareness (SCCS 2009; SCHER 2012). This is 
especially true if a vulnerable group of the population, e.g. 
children, may be affected by substances interfering with the 
development of children or unborn life. Profound toxico-
logical knowledge and a high level of expertise are required 
to adequately assess the wealth of data on these topics and 
to draw the right conclusions in order to protect consumers 
and address public concerns without fuelling fears.
Environmental health (outdoor and indoor air, drinking 
water, watercourse, soil)
Breathing air, drinking water, and eating food are major 
sources of exposure to xenobiotic substances. Limit or 
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guideline values for many environmental substances have 
been established to prevent adverse human health effects 
(WHO 2010, 2011). The derivation of these values has to 
consider potential adverse health effects, but also geogenic 
contaminants and anthropogenic load. The quality of drink-
ing water and outdoor air in Europe is tightly regulated and 
regularly monitored; the toxicological risks arising from 
substances which may be present in water and outdoor air 
are generally well characterized. Toxicological assessments 
and recommendations for guideline levels are available for 
indoor air (SCHER 2007). The toxicological assessment of 
risks arising from fine dust (respirable particulate matter, 
PM10) still represents a challenge (Andersen et al. 2012; 
Raaschou-Nielsen et al. 2011; Shah et al. 2015), and health-
based limit values are often exceeded. New challenges arise 
from rare emissions occurring in accidents and from indi-
rect effects resulting from global warming, e.g. increasing 
levels of mycotoxins as food contaminants (Paterson and 
Lima 2010). A comprehensive assessment of environment-
related adverse health effects demands profound toxico-
logical expertise combined with a detailed knowledge of 
environmental emissions and immissions.
Safety pharmacology
Drug toxicology (also termed pharmaceutical toxicology or 
safety pharmacology) is the study of the potential undesir-
able effects of drug candidates and drugs in the therapeutic 
range and above. This is a prerequisite for clinical studies. 
Traditionally, toxicological testing of new drugs was per-
formed according to a standard study programme (Kinter 
and Valentin 2002; Pugsley 2005). More recently, pre-clinical 
testing has been tailored to the specific properties and mode-
of-action of the new drug and may be adapted based on the 
outcome of previous studies (Pugsley et al. 2011). This flexi-
ble, tailor-made approach is accommodated by the regulatory 
registration process. New types of drugs (e.g. oligonucleo-
tide therapeutics and stem cells) present new challenges and 
demand newly developed test systems and novel concepts to 
assess the results of these studies (Muller and Milton 2012).
In drug development projects, toxicology—closely 
linked with pharmacology and pharmacokinetics—is deci-
sive in the success (or failure) of a new drug candidate 
during pre-clinical and early clinical testing. Any misinter-
pretation of substance properties cannot be rectified in the 
later stages and thus causes expensive failure of the whole 
project. Toxicology therefore generates value by timely 
elimination of non-eligible drug candidates (‘fail early and 
cheap’) and enables reliable risk assessments and risk man-
agement in early clinical trials. The notion that toxicology 
‘kills’ drug candidates is obsolete; what toxicology actually 
does is to push drug development projects towards valuable 
drug candidates.
Clinical toxicology
Clinical toxicology links preventive and experimental toxicol-
ogy with clinical medicine. This area of toxicology has under-
gone profound changes during the last decades: traditionally 
clinical toxicology was concerned with the diagnosis and 
treatment of acute intoxications (i.e. reduction of absorption, 
accelerated elimination, and antidotes). Hence, clinical toxi-
cology was used primarily by emergency physicians (Hahn 
2009). The incidence of acute intoxications has decreased, 
however, during the past few decades due to the development 
of safer products (a merit of toxicological research), espe-
cially safer drugs with a wide therapeutic index. However, 
effective antidotes for acute intoxications, e.g. for death cap 
fungus (Amanita phalloides) poisoning, are still needed. This 
requires a detailed knowledge of fungal toxins (amongst oth-
ers, α-amanitin) and their toxic mechanisms, as well as repair 
mechanisms in the damaged organ (the liver) (Müller and 
Desel 2013). The investigation of further toxins of animal, 
plant and microbial origin (e.g. botulism) and infections (e.g. 
Clostridium difficile-associated diarrhoea and diphtheria) 
has revealed their toxic mechanisms and paved the way for 
future potential therapies and applications in drug design, e.g. 
‘molecular Trojan horses’ (Barth and Stiles 2008).
Competence in clinical toxicology comes together in 
poison control centres which gather experimental and clini-
cal data on a wide range of different substances (Sutter 
et al. 2010). Poison control centres provide toxicological 
risk assessments after acute and chronic exposure cover-
ing cases with mild intoxication or subclinical intoxication. 
Rapid and reliable information on the toxicological profile 
of a substance is the basis for recommendations of effective 
treatments (or giving the ‘all-clear’) and has significantly 
improved medical care.
Current scientific topics in toxicology
Toxicological research in the past
In the past, toxicological research was not mainly preven-
tive. The need for this did not become evident until expo-
sure-related severe health impairments had been observed 
in many people. Examples are the well-known disasters 
due to thalidomide (Contergan®, induced phocomelia and 
amelia), asbestos (lung cancer and pleural mesothelioma), 
aromatic amines (cancer of the urinary bladder in painters 
and industry workers), arsenic (skin cancer), and contact 
allergies to substances encountered in everyday life, and in 
the environment. Research into asbestos, which was started 
after recognizing asbestos-induced cancer, resulted in new 
knowledge on the mode of action not only of asbestos 
fibres, but of fibres in general.
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It was demonstrated that bio-persistent fibres with a cer-
tain geometry—‘critical fibres’—induce chronic inflam-
mation in the lungs due to their ability to trigger incom-
plete (‘frustrated’) phagocytosis associated with massive 
activation of macrophages and release of pro-inflammatory 
mediators (Gibbs and Hwang 1980; Rom et al. 1991). 
This knowledge led to the recognition that newly devel-
oped nanomaterials with an asbestos-like geometry might 
cause similar effects. It was therefore possible to prevent 
the induction of lung damage by such materials during their 
development and a long time before they became commer-
cially available (Gebel et al. 2014).
It became evident that the severe health impairment and 
disease in humans exposed to the above-mentioned sub-
stances occurred because there was not enough knowledge 
on the toxicological profile of these substances to enable 
the risks to be recognized, which would have resulted in 
concrete advice on minimization of exposure.
A principal aim of toxicological research, therefore, is to 
identify potential risk factors before exposure of humans to 
toxic substances, in particular where the damage or disease 
occurs after a long latency period. A paradigm change is 
therefore needed here to establish the concept of preventive 
toxicology.
Selected areas of current toxicological research
Carcinogenesis: mechanisms and threshold values
In real life, humans are exposed to a variety of carcinogenic 
substances in food, in the environment, and at the workplace. 
According to the current paradigm for genotoxic carcino-
gens, it would be best to completely avoid exposure to such 
substances. There are, however, mechanism-based arguments 
that complete prevention of exposure might not be necessary 
(Johnson et al. 2009). This means that identification of the 
most critical carcinogens, elucidation of the molecular mech-
anism underlying their adverse mode of action, and of cel-
lular repair mechanisms are extremely important (Oberemm 
et al. 2009). The knowledge of such mechanisms enables the 
decision whether threshold levels can be identified below 
which no carcinogenic effects should be expected (Bolt et al. 
2004). The identification of the molecular and cellular mech-
anisms underlying the cancer-inducing potential of chemi-
cals is the crucial step in science-based risk management.
Endocrine‑active compounds and non‑monotonic dose 
responses
Endocrine-active substances can interfere with the endocrine 
system by mimicking hormones or inhibiting their functions, 
or by stimulating or inhibiting the synthesis of hormones in 
the body. The relevance of endocrine-active substances for 
human health is a subject of controversy (Lamb and Boffetta 
2014). Many scientists believe that thresholds exist and that 
normal risk assessment paradigms are appropriate for these 
substances, also in the light of very low exposure levels and 
the low intrinsic activity of most endocrine-active substances 
(Autrup et al. 2015; Borgert et al. 2013; Testai et al. 2013). 
These authors emphasize that the extensive database for the 
potent hormone diethylstilbestrol is consistent with dose-
related effects for adverse outcomes in animals and humans. 
Other authors do see a risk because of the combined effects of 
various similarly acting substances and suggest a non-mono-
tonic dose–response model for hormonally active compounds, 
implying that low-level exposure conditions might be relevant 
(Vandenberg et al. 2012; Zoeller et al. 2014). Recently, a possi-
ble contribution of endocrine-active compounds to the increas-
ing prevalence of diabetes and obesity has been discussed.
The concerns about potential endocrine-mediated health 
hazards have resulted in many activities in the field of 
regulatory toxicology (e.g. EFSA 2013; SCCS 2015). The 
Organization for Economic Cooperation and Develop-
ment (OECD) in their ‘Conceptual Framework for Testing 
and Assessment of Endocrine Disruptors’ gives informa-
tion on data sources and the different test systems avail-
able and under development. The OECD has developed, 
optimized, and validated numerous in vitro and in vivo 
methods for testing the endocrine activity of substances 
and related effects (mammalian and non-mammalian toxic-
ity). These activities must be continued in order to develop 
novel assays based on a better understanding of the mecha-
nisms underlying the regulation of endocrine effects in the 
organism. The current controversies demonstrate the urgent 
need for further basic research to elucidate the discrepan-
cies between the results obtained by in vitro test systems 
and animal studies, and their relevance for humans. Most 
important in this context is a better understanding of hor-
monal signalling pathways and related disorders, in par-
ticular those for the thyroid hormones, and the detection of 
such disorders by appropriate test systems (EFSA 2013).
Toxicity of mixtures of substances
Toxicological research has so far focused on investigat-
ing the mechanisms by which single compounds interfere 
with biological processes. However, in real life, humans are 
exposed to a variety of compounds at the same time, for 
example at the workplace, or via (multiple) contaminants 
in food, in the air, or the environment. Several approaches 
have been proposed to take into account the action of com-
bined substances.
Previous (non-systematic) studies suggested that the 
adverse effects of mixtures of toxins were smaller than would 
be expected from addition of the individual effects caused 
by the single substances in mixtures (‘additive model’) 
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(Hertzberg et al. 2013). However, there are well-known 
exceptions: substances inducing enzymes, which metabolize 
and thereby activate chemicals, show stronger than additive 
effects in combination with their substrate chemicals; the 
same holds true for combinations of genotoxic carcinogens 
in combination with substances that inhibit DNA repair sys-
tems (Kortenkamp et al. 2012; Ermler et al. 2014).
Some of the approaches suggested are rather pragmati-
cally oriented and lack a scientific basis for the toxicologi-
cal assessment of the action of a combination of chemicals. 
Combined effects caused by mixtures of substances are espe-
cially relevant in the combined assessment of human health, 
and further research is needed to establish a knowledge-
based system of assessing potential adverse effects caused by 
simultaneous exposure to different toxic substances at levels 
below their individual NOAEL (SCCS, SCHER, SCENIHR 
2011). The substance mixtures requiring investigation could 
be ranked by urgency based on our knowledge of human 
exposure to such mixtures in food and drugs, at the work-
place, and in the environment (Carlin et al. 2013).
Immunotoxicity
Adverse effects of substances can be mediated by the 
immune system (IPCS 2012; Rooney et al. 2012). A reac-
tion of the immune system contributes to conditions such as 
allergic contact dermatitis and asthmatic symptoms. With 
a prevalence of about 15 %, contact dermatitis is amongst 
the most frequent diseases induced by chemicals, including 
cosmetic ingredients (Belloni-Fortina et al. 2015). Sensiti-
zation testing is essential to be able to warn and to prevent 
exposure. Because animal testing for cosmetic products and 
their ingredients has been banned since 2013 (EU 2003), 
much has been invested in the development of novel toxi-
cological test systems to address this endpoint (Mehling 
et al. 2012; Basketter et al. 2013; Reuter et al. 2015).
Besides sensitization reactions, the immune system is 
also involved in ‘idiosyncratic’ toxicity of the liver (Chalas-
ani and Björnsson 2010). The immune system is trained to 
recognize and eliminate foreign structures. Genome-wide 
comparison with our phylogenetically closest relatives sug-
gests a significant evolutionary pressure to develop a highly 
efficient immune system. This comes, however, at a cost, 
i.e. frequent and undesirable immunoreactions following 
exposure of humans to chemicals. To be able to predict 
such immunotoxic reactions, significant future efforts in 
the field of basic research are required. One complication, 
however, is that the transfer of results from animal models, 
in particular mouse models, to the human situation is rarely 
possible. It recently became evident that inflammatory pro-
cesses in the brain play a role in acute events in this organ 
(ischaemia), but also in age-related neurodegenerative 
diseases such as Alzheimer’s, and there are hints that the 
reaction of the brain tissue towards substances encountered 
in daily life might play a role in these processes (Heneka 
et al. 2015). Because of the dramatic increase in neurode-
generative diseases, this topic will become an important 
interdisciplinary field of activity requiring toxicological 
expertise.
Toxicity of nanomaterials (nanotoxicology)
Nanotechnology is one of the key technologies of the 
twenty-first century. Ongoing toxicological research on 
nanomaterials has resulted in sustainable development of 
such materials and their broad acceptance by consumers. 
Nanomaterials are not only used as industrial intermedi-
ates, but also used for consumer-oriented everyday products 
(such as cosmetics, food, packaging, clothing). Moreover, 
nanoparticles are considered useful tools in the field of med-
ical therapy and diagnostics, e.g. ferric oxide nanoparticles 
as transporters for anticancer drugs or as contrast agents for 
magnetic resonance imaging (Abakumov et al. 2015).
Toxicological investigations to assess the risk of newly 
developed nanoparticle systems are challenging tasks at 
the interface between biology, medicine, pharmacy, chem-
istry, and physics. Existing test guidelines for chemicals 
are generally applicable to nanomaterials, but may need 
amendment with regard to test item preparation and char-
acterization. Depending on the route of exposure (dermal, 
oral, inhalation, intravascular for medically used particles), 
the choice of the relevant test system plays an important 
role. Surprisingly, in vitro methods play only a minor role 
in nanotoxicology assessments, most likely because of the 
limited characterization of nanomaterials in test systems, 
the choice of non-relevant concentrations of the test mate-
rial, and insufficient knowledge of the dose in vitro. For the 
toxicological assessment of nanomaterials, both the vari-
ety of materials and their different applications pose chal-
lenges, and it will not be possible to completely test every 
nanomaterial in every test system. Strategies for grouping 
nanomaterials for toxicological assessment are therefore 
required (Gebel et al. 2014; Arts et al. 2014, 2015; Godwin 
et al. 2015). Important in the context of nanotoxicologi-
cal research are questions regarding the uptake, mobility 
and deposition of nanomaterials in the body, the effects of 
nanomaterials after inhalation and oral intake, and the long-
term effects of nanomaterials (Savolainen et al. 2013). Cur-
rently, a comprehensive research consortium is investigat-
ing the long-term effects of nanoparticles after their uptake 
into the body via inhalation (Gebel et al. 2014).
Developmental neurotoxicity
There is evidence that disorders of intellectual abilities 
and mental health are increasing. A committee of the US 
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National Research Council has estimated that develop-
mental disorders are to 3 % a consequence of an exposure 
against environmental influences and further 25 % a direct 
consequence of an interaction between environmental fac-
tors and genetic pre-disposition (see Landrigan et al. 2012). 
Since the existing toxicological routine test systems are 
not suitable to detect this kind of developmental disorders, 
there is pressure need to develop more adequate test sys-
tems, which are sensitive enough on the one hand (Balmer 
et al. 2014; Zimmer et al. 2014) and enable the interpreta-
tion whether the obtained results are relevant for humans.
Although an OECD guideline (TG 426 Developmental 
Neurotoxicity study) was established more than 10 years 
ago, there is still significant missing knowledge on this 
topic, i.e. there is an urgent need to develop adequate meth-
ods (Makris et al. 2009; Saunders et al. 2012). It is worth 
noting that the interpretation of data from animal studies 
is very difficult, and decisions whether subtle results from 
animal studies are relevant or not for humans require elabo-
rate, long-term epidemiological studies.
Research into developmental neurotoxicity must be 
deepened and presents a particular challenge because of 
the large number of potentially harmful chemicals in wide-
spread use, and because of the controversy on how to inter-
pret results from animal studies (Berghuis et al. 2015).
New challenges and novel approaches
In silico toxicology
In silico toxicology, also known as computational toxicol-
ogy, is a novel strategy in toxicology which aims to estab-
lish mathematical models based on existing knowledge and 
to use these for making predictions. A feature of in silico 
toxicology is its high degree of interdisciplinarity, linking 
modern toxicology with bioinformatic and chemoinfor-
matic methodologies. The concept that the biological activ-
ity of a chemical compound is implicitly determined by its 
chemical structure is, as such, not new (Collins et al. 2008). 
Only a few years ago, the term ‘in silico toxicology’ was 
mostly used for the prediction of potential toxicity based 
on physicochemical or structural properties of chemicals. 
Nowadays, the term is used in a wider sense and covers 
predictions based purely on structure, as well as toxicity or 
more general effect profiles.
Databases with information on chemical structure 
and effect, and chemical structure and adverse modes of 
action (including data from high-throughput technolo-
gies on adverse outcome pathways), form the basis for 
the recognition of some patterns that may be generalized. 
In theory, a new rule for an expert system or a quantitative 
structure–activity relationship can be deduced for each tox-
icological endpoint via data evaluation and statistical anal-
yses. If, in an ideal situation, the toxic effect can be associ-
ated with a known mechanism of action, MOA, or—even 
better—if links with an ‘adverse outcome pathway’ can be 
established, this type of statistical analysis is promising. If, 
however, the toxic effect is the result of several different 
mechanisms working sequentially or simultaneously, then 
reliable prediction is still difficult at present (Knudsen et al. 
2015).
In principle, one can distinguish between (a) evidence-
based expert systems that derive rules concerning the rela-
tionship of structure and toxicity from existing data, based 
on the recognition of ‘structural alerts’; and (b) statistics-
based systems that use descriptors (structural and phys-
icochemical parameters) to derive quantitative correlations 
between structure and effect.
In silico methods require high-performance data stor-
age and computing and have therefore developed only 
recently. The increasing number of publications in lit-
erature databases (e.g. PubMed) over the last 10 years on 
the topic ‘QSAR’ and ‘in silico’ highlights their increas-
ing importance. Likewise, the volume of funding for this 
kind of research, e.g. through EU grants, has been high. 
For instance, in silico methods play a central role in the 
European SEURAT-1 Research Initiative and the ‘eTOX’ 
project funded by the Innovative Medicines Initiative. In 
the context of the reorientation of Toxicology (TOXCAST 
und ‘tox21’) promoted by the US Environmental Protection 
Agency (EPA), in silico toxicology is playing a major part 
in the paradigm change away from animal testing towards 
toxicological assessment of alternatives by using a combi-
nation of molecular biology and ‘omics’ techniques includ-
ing computational methods.
In vitro methods
Primary cell cultures have always been the gold standard 
for in vitro testing. However, conventional two-dimen-
sional (2D) cultures of primary cells tend to undergo de-
differentiation and lose their organotypic functions. More 
complex techniques of cell culturing, including 3D cultures 
(e.g. collagen sandwich models, co-cultures, hanging drop, 
spheroids) and tissue engineering are capable of mirroring 
complex cell–cell interactions (Alépée et al. 2014). The 
priority is to mirror the natural context of the tissues of an 
organ. Commercial application of such systems has already 
started, and these systems display dose–effect profiles that 
are indeed closer to in vivo systems than classical cell cul-
ture methods.
New developments in the area of dynamic cell culture 
using bioreactors are also enabling the in vivo-like transport 
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of compounds in an in vivo-like tissue context, thus going 
one step forward towards more realistic exposure scenarios. 
By miniaturizing such systems, bioreactors are likely to 
become more broadly applicable. Such ‘microfluidic’ sys-
tems are the basis for the development of ‘organ-on-a-chip’ 
models (Kelm and Marchan 2014). In such assemblies, 
multichannel 3D microfluidic cell culture chips are used, 
which comprise all or at least a representative fraction of 
cell types in a tissue in their natural 3D context. Based on 
their dynamic culture conditions, such systems are able 
to mirror the activity status and also the mechanistic and 
physiological reactions of an organ. As a next step, several 
organ systems can be combined to enable systemic investi-
gation of toxic effects.
In view of the limited access to human tissue, stem cells 
are likely to gain more and more importance as a replace-
ment for primary human cells. Much work is still needed 
to optimize techniques based on embryonic stem cells and 
induced pluripotent stem cells (iPS) before the properties 
and activities of such cell models are similar to those of the 
corresponding primary cells. Cells from animals, represent-
ative cell lines, and genetically modified cells have played 
an important role in the validation of methods and will con-
tinue to do so (Adler et al. 2011).
Predictivity for the in vivo situation in humans with 
modern in vitro methods is steadily growing. Unfortu-
nately, however, in vitro methods that are rather close to 
in vivo often fail due to technical limitations in assessing 
their validity (standardization and overall reproducibility). 
In complex culture systems, specific key aspects of biologi-
cal processes are gaining more and more attention, but at 
the same time the standardization, quality control and inter-
pretation of results is becoming more difficult. For this rea-
son, modern in vitro methods should be kept as simple as 
possible but as sophisticated as necessary, to guarantee sat-
isfactory answers to future scientific questions. Integrated 
testing strategies (ITS), as opposed to single definitive 
tests, are expected to efficiently combine different in vitro 
methods. Validation of modern in vitro methods has been 
and will continue to be a challenge (Jennings et al. 2014; 
Rovida et al. 2015).
‘Omics’ methods and their interpretation
In scientific research, the term ‘Omics’ analysis refers to 
the parallel assessment of all molecules or modifications 
of molecules of a certain type in a given sample. Examples 
are the assessment of all RNAs (transcriptomics), proteins 
(proteomics), or metabolites (metabonomics, also called 
metabolomics). Meanwhile, also epigenetic changes, such 
as cytosine methylation in DNA or various kinds of post-
translational modifications of histones, can be detected via 
‘epigenomics’. Applying such methods in toxicological 
research enables the comparative analysis of substance-
induced changes at various molecular levels in a in a single 
study.
Apart from the biological model and the technology 
used for measurement of gene expression, the strategy for 
statistical analysis and interpretation are of crucial impor-
tance in toxicogenomic experiments (Rahnenführer and 
Leist 2015). Often software is being used that, on the one 
hand, produces lists of significantly deregulated genes and, 
on the other, enables more complex analyses such as testing 
for overrepresentation of certain functions and signalling 
cascades. How to find the best biological interpretation of 
the massive amounts of complex datasets and to view these 
from the toxicological perspective is a challenge, even for 
the most highly skilled professionals, and clearly calls for 
the expertise of toxicologists trained in both classic and 
modern toxicology. Routine deployment of such techniques 
in drug development is not yet possible.
Existing data may yield information on dose-dependent 
(in vivo) or concentration-dependent (in vitro) biological 
responses. The focus is on the elucidation of mechanisms 
underlying toxic effects, of both individual compounds and 
classes of compounds (Andersen et al. 2015).
In the area of cellular deregulation, usage of the above 
methods aims to identify molecular signatures for the clas-
sification of adverse effects in vivo and for prediction. But 
since non-adverse influences, such as eating or a change of 
culture media, can also lead to purely adaptive responses 
in ‘omics’ studies—which may come close to the level of 
deregulation seen after drug treatment—it is inappropriate 
to interpret any drug-induced change in expression as an 
adverse effect.
An important and challenging task of basic science 
therefore is to identify the dose (or concentration) range 
where responses have primarily adaptive functions, depend-
ing on the magnitude and duration of the response, and on 
the simultaneous activation of other signalling pathways. It 
will certainly not be possible to generally deduce from the 
absence of changes in the target cells that a given substance 
is harmless at the chosen dose. If, however, it were possible 
to establish such a relation for a specific form of toxicity, 
this could help simplify future toxicological risk assess-
ment (Oberemm et al. 2005; Ellinger-Ziegelbauer et al. 
2008; Thomas et al. 2011).
A number of applications highlight the aims that may be 
pursued with these methods, such as (a) diagnostic classi-
fication of organ damage or prediction of chronic changes 
based on changes in gene expression in experimental stud-
ies. One potential use is the prediction of carcinogenicity in 
the context of prioritizing chemicals for long-term studies, 
in view of the large number of compounds awaiting testing; 
(b) establishment of ‘health-based guidance values’ such as 
reference dose, ADI or TDI, in which, based on deregulated 
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genes or their functions or signalling pathways, a point 
of departure is determined via ‘benchmark dose model-
ling’ and used to derive the respective health-based guid-
ance value; (c) prediction and identification of toxicity via 
metabolite profiling; (d) characterization of ‘toxicological 
pathways’ (adverse outcome pathways), which are viewed 
as one of the most important results and tools of the science 
of toxicology in the twenty-first century and are considered 
fundamental to a better general classification of the effects 
of chemicals (Burden et al. 2015).
Implementation of physiologically based toxicokinetic 
modelling
Toxicokinetics relies on the same principles as pharma‑
cokinetics, but there are differences in data availability 
and aims. In pharmacokinetics, the typical approach is to 
run experimental studies yielding large amounts of data. 
For toxicokinetics, however, this procedure is not suitable. 
Instead, physiologically based kinetic models have gained 
special importance for toxicology and have been recog-
nized as a valuable tool to explain toxicity phenomena 
and underlying mechanisms (Bessems et al. 2014). Physi-
ologically based (toxico-)kinetic modelling (PBTK) neces-
sitates (a) a systemic approach that can mirror physiologi-
cal processes of kinetics in a structural and a mathematical 
model; and (b) implementing the numerical algorithms by 
flexible programing that enables use in various scenarios. 
Using a ‘bottom-up’ approach, individual compound-spe-
cific parameters are determined in independent systems, 
often in vitro or in silico, and then incorporated into a 
single model for the whole body. PBTK models have the 
great advantage that—based on knowledge of physiological 
processes—the effect of changes in physiology can be pre-
dicted on the concentration–time course, even in an indi-
vidual organ. Changes in physiology may include reduction 
of xenobiotic metabolism in premature infants or changes 
in pregnancy. Coupled with dose–effect models, prediction 
of effects and their magnitude is possible (Mielke and Gun-
dert-Remy 2012). A promising area of future development 
is the implementation of interindividual variability, which 
can predict the behaviour of the general population across 
all age classes and special features (Zeise et al. 2013); 
another area is to establish new structural models for the 
prediction of the time course of intracellular drug concen-
trations as well as in cell organelles that are linked with 
the mechanisms of action. The same is true for modelling 
of the time course of concentrations in in vitro systems, 
also called reverse PBTK or in vivo–in vitro extrapolation 
(Coecke et al. 2013). The latter approach is based upon 
the idea that the toxic effect is more closely linked with 
the time course of drug concentration at the site of action 
than with external exposure, as determined in food, in the 
ambient air at the workplace, or in cell culture medium in 
in vitro systems.
Implementation of this approach and its further devel-
opment as an interdisciplinary activity is a promising step 
towards the development of both in vitro systems (Schug 
et al. 2013) and a new pillar for improved risk assessment. 
Many of these new approaches have been set up and evalu-
ated in non-academic institutes of toxicology, indicating 
that university departments are lagging behind in their 
expertise.
Current scientific topics in risk assessment
Impact and significance of alternative methods
In silico methods and in vitro systems are traditionally 
much used approaches to complement or partly replace 
animal tests in toxicology. Long established are in vitro 
genotoxicity tests that allow conclusions to be drawn on the 
genotoxic and mutagenic properties of a chemical, often 
without the need for further in vivo testing. Also estab-
lished are several alternative methods for eye and skin irri-
tation testing and the use of primary hepatocytes for metab-
olism and interaction studies (Adler et al. 2011; Basketter 
et al. 2012; JRC 2014).
In view of (a) test requirements for a large number of 
chemicals in the REACh Regulation, (b) limited capacities 
for in vivo toxicity testing, and (c) for reasons of animal 
protection, further development of reliable and time-saving 
alternative (non-animal) tests is of particular importance, 
let alone the political interest in animal protection (EU 
2003). Compared to in vivo models, the in vitro methods 
are often reductionist, less complex models, and have limi-
tations when the interplay between multiple cell types (e.g. 
in liver toxicity) or various tissues (e.g. in endocrine dereg-
ulation) causes a toxic effect (Lilienblum et al. 2008).
Often ‘integrated test strategies’ which combine in sil-
ico, in vitro, and in vivo methods allow the best predictions 
of toxicity in humans. Against this background and because 
of the ban on animal tests for toxicity testing of cosmetic 
ingredients, several EU-funded programmes have been ini-
tiated, one of the aims being to develop in vitro systems for 
the detection of organ toxicity (Andersen et al. 2015).
Unfortunately, these research programmes are reach-
ing their limits in some cases due to politically motivated 
restrictions on conducting research exclusively with human 
cell systems. Accompanying research in animal models was 
not sponsored by such EU-funded research programmes. 
The result is that it has been very difficult to assess the 
in vivo relevance of the data generated for numerous 
1889Arch Toxicol (2015) 89:1881–1893 
1 3
substances with human in vitro systems only. Thus, it is 
necessary to conduct additional studies in the context of a 
classical ‘parallelogram strategy’ to assess (a) the in vivo 
relevance of in vitro rodent systems data; and (b) the 
human relevance of in vitro rodent systems. Thereby, then 
several alternative test methods developed within the EU 
programme can be assessed for their in vivo relevance.
Exposure: external versus internal exposure
For a toxicological risk characterization, along with con-
siderations of hazardous properties, mode of action and 
dose–response characteristics of a given compound, expo-
sure assessment is an indispensable element. It must take 
into account all intake routes (by inhalation, oral, der-
mal). Depending upon the existing compound concentra-
tions, its physicochemical properties and the intake route, 
such external exposure, will result in different internal 
exposures.
Sensitive analytical methods serve to determine contam-
inant levels present in various media (e.g. air and food) and 
allow conclusions on external exposure or for the surveil-
lance of limit values for hazardous chemicals at the work-
place (OELs). To assess internal exposure, two approaches 
can be taken: (a) physiologically based toxicokinetic mod-
elling (PBTK, see above); and (b) compound-specific 
analysis in biological samples (blood, urine) collected in 
human biomonitoring (HBM) studies. Both (complemen-
tary) approaches require special expertise. The relevance 
of PBTK and HBM for scientifically based risk assessment 
is beyond dispute and will gain increasing international 
importance (Aylward et al. 2013).
HBM studies assess existing exposure from all sources 
(aggregate exposure) in populations. Since biomarker data 
reflect individual factors such as intake, metabolism, and 
excretion, HBM is an improvement over conventional esti-
mates of (external) exposure. HBM studies with a suitable 
design can also reveal trends over time in contaminant bur-
den or in subpopulations (Den Hond et al. 2015). Newly 
developed methods with simultaneous analysis of biomark-
ers for groups of chemicals (e.g. mycotoxins, phthalates, 
preservatives) will enable better surveys on combined 
human exposures (see above, mixtures).
The opportunity of improved exposure assessment by 
HBM also presents new challenges with regard to interpre-
tation and communication of data (Exley et al. 2014). The 
detection of a chemical or its metabolite in body fluids by 
highly sensitive analytical methods is not equivalent to a 
‘danger’. The careful scientific interpretation of biomoni-
toring results needs to take into account the data on dose–
effect relationships from animal studies, and, to allow for a 
human equivalence dose approach, the internal concentra-
tion related to the doses.
Sensitive subgroups/individuals in the population
Whether exposure to chemicals presents a health risk in an 
individual or a population is evaluated on the basis of dif-
ferent factors, i.e. data on adverse effects, the dose–effect 
relationship, the dose without any adverse effects, and the 
extent of human exposure. It is obvious that the extent of 
exposure varies between individuals: newborns and infants 
have a higher food intake in relation to body weight than 
adults, which is an important aspect in food contaminant 
assessments. Infants have a higher ratio of body surface 
area to body mass index than older children and adults, 
which may lead to a higher dermal uptake per kg body 
weight. Moreover, when excretion of xenobiotics is slower, 
the same external dose can result in higher internal concen-
trations (internal exposure) than in adults (Abraham et al. 
2005; Mielke et al. 2005). Due to these factors, infants and 
toddlers are regarded as a sensitive subgroup in the popula-
tion. Whereas means are at hand to correct the safe dose 
for the differences in kinetics, it is more difficult to take 
into account the potentially higher sensitivity of the devel-
oping organism and possible irreversible effects later in life 
(WHO 2006). Special attention is therefore paid to chemi-
cal exposure during the pre- and postnatal stages (‘criti-
cal windows of exposure’), notably in a risk evaluation of 
endocrine-active compounds. So far, there are no widely 
accepted and human-relevant test methods for important 
functions such as immunocompetence and intellectual 
development. There is as yet no consensus whether persons 
of advanced age need to be considered separately in risk 
assessments. With regard to exposure via food, separate 
exposure values are already determined for ‘the elderly’ 
(>65 years) and occasionally ‘the very elderly’ (>80 years).
Genetic polymorphisms in xenobiotic-metabolizing 
enzymes and transport proteins in individuals or subpopu-
lations have been known for quite some time as the toxi-
cokinetic basis for a higher sensitivity to certain drugs or 
chemicals (Scheuplein et al. 2002). To account for this 
when evaluating toxic chemicals and deriving ‘safe’ doses 
and exposure periods, procedures have been set by conven-
tion which arrive, however, at overly conservative estimates 
(Alexeeff and Marty 2008; Dourson et al. 2002; Ginsberg 
et al. 2004). Improved statistical modelling could lead to 
more realistic estimates. Also known are genetic polymor-
phisms in genes, e.g. DNA repair genes, which modulate 
the effects of xenobiotics (Woo et al. 2014). Further con-
ceptual work is, however, needed to establish how this 
knowledge can be quantitatively implemented.
Adaptive (responses) and adverse changes
Toxicological risk assessment is not a rigid procedure or 
routine; instead it incorporates scientific developments 
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and new conceptual questions as they occur. One impor-
tant task in the context of novel methods of characteriz-
ing effects of chemicals (see section "New challenges and 
novel approaches") will be to develop tools to define called 
pathways of toxicity or adverse outcome pathways (Bur-
den et al. 2015). Furthermore, the development of criteria 
to distinguish between adaptive responses and adverse 
changes (Keller et al. 2012) will become extremely impor-
tant. The background for the latter are changes observed 
in ‘omics’ studies where harmless influences, e.g. feeding 
or exchanging culture medium, led to expression changes 
which may have come close to the level of drug-induced 
deregulation in cells (see section “‘Omics’ methods and 
their interpretation”) (Zhang et al. 2014). Valid evaluation 
in the future will therefore have to be supported by more 
extensive basic research.
Conclusions
Toxicology is a translational science and an academic disci-
pline in its own right. As a scientific discipline, toxicology 
aims to discover the mechanisms underlying health impair-
ments caused by substances. Basic research is essential to 
this task.
Basic research that investigates and identifies the mecha-
nisms by which exposure to substances interferes with the 
functions of biomacromolecules, cells, organs, organism 
and—in a wider sense—ecosystems, and the consequences 
of such dysfunctions, should be directed towards the final 
objective, namely how the results can be translated into 
safeguarding human health. This means that applied toxi-
cological test systems have to demonstrate their robust-
ness, significance and relevance: in vivo relevance must 
be defined for in vitro test systems, and for animal models 
the relevance of the research results for humans must be 
established.
Much effort has been invested in establishing the con-
cept of ‘preventive toxicology’ over the past few decades. 
In doing so, potential risk factors have been identified 
using the most modern and sensitive methods. This concept 
should be expanded in such a way that safety assessments 
are integrated into the development of new technologies. 
Toxicology will cover the potential effects on human health 
in this concept.
To meet the challenges of this concept, toxicology needs 
constant improvements in methodology and implementation 
of novel approaches, including (a) in silico toxicology (com-
putational toxicology); (b) in vitro methods complementing 
and replacing animal testing; (c) ‘omics’ approaches includ-
ing transcriptomics, proteomics, metabonomics, and ‘epi-
genomics’; and (d) physiologically based (toxico-)kinetic 
modelling. Implementation of such approaches and their 
further development and refinement will improve the assess-
ment of risks to human health. Success, however, clearly 
depends on interdisciplinary collaboration, as these new 
approaches require a broad array of expertise in different 
areas of basic scientific research. Many of these approaches 
are currently being established and evaluated in non-aca-
demic institutes of toxicology, which indicates that univer-
sity departments are lagging behind. Academia should be 
taking the lead in setting up networks with industry and reg-
ulatory institutions in order to fulfil its role in the education 
of young researchers. Toxicological research at the univer-
sity level should be strengthened, and the discipline should 
be supported by the authorities responsible for the environ-
ment and the health of consumers and workers. Even the 
authorities responsible for economic development should be 
interested in sound toxicological science as a basis for inno-
vative and sustainable products.
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